Citation Impact
Citing Papers
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics
2006
Oxidative Stress
2017 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples
2010
Astrocytes: biology and pathology
2009 Standout
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy
2008
The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study
2010
New Developments in Anthracycline-Induced Cardiotoxicity
2009
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
Targeting hypoxia in cancer therapy
2011 Standout
Acute downregulation of Cx43 alters P2Y receptor expression levels in mouse spinal cord astrocytes
2003
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
2012 Standout
Doxorubicin pathways
2010 Standout
SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK)
2010
Identification of natural inhibitors of Entamoeba histolytica cysteine synthase from microbial secondary metabolites
2015 StandoutNobel
Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase
2005
Deletion of Astrocyte Connexins 43 and 30 Leads to a Dysmyelinating Phenotype and Hippocampal CA1 Vacuolation
2009
Flavonoids as protectors against doxorubicin cardiotoxicity: Role of iron chelation, antioxidant activity and inhibition of carbonyl reductase
2007
Design of anticancer prodrugs for reductive activation
2008
Advances in metal-induced oxidative stress and human disease
2011 Standout
Cardioncology: State of the heart
2013
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
2005
Biodegradable luminescent porous silicon nanoparticles for in vivo applications
2009 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Neuronal sensitivity to hyperoxia, hypercapnia, and inert gases at hyperbaric pressures
2003 StandoutNobel
The Science of Stroke: Mechanisms in Search of Treatments
2010 Standout
New iron chelators in anthracycline-induced cardiotoxicity
2007
Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity
2006
Glial connexins and gap junctions in CNS inflammation and disease
2008
ATP mediates rapid microglial response to local brain injury in vivo
2005 Standout
Pyridoxal Isonicotinoyl Hydrazone (PIH) and its Analogs as Protectants Against Anthracycline-Induced Cardiotoxicity
2008
Connexins 26, 30, and 43: Differences Among Spontaneous, Chronic, and Accelerated Human Wound Healing
2004
Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review
2012
Connexon connexions in the thalamocortical system
2005
Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: A study of salicylaldehyde isonicotinoyl hydrazone (SIH)
2007
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1
2011
Dissecting the Role of Multiple Reductases in Bioactivation and Cytotoxicity of the Antitumor Agent 2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1)
2008
Two Nonsynonymous Single Nucleotide Polymorphisms of Human Carbonyl Reductase 1 Demonstrate Reduced in Vitro Metabolism of Daunorubicin and Doxorubicin
2009
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
2011
Drug repurposing: progress, challenges and recommendations
2018 Standout
N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology
2007 Standout
Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review
2018 Standout
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
Physiology and Pathophysiology of Purinergic Neurotransmission
2007 Standout
Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage
2019 Standout
Gap junctions in CO2-chemoreception and respiratory control
2002
Gap junctions and connexin expression in the normal and pathological central nervous system
2002
Electrical Coupling and Neuronal Synchronization in the Mammalian Brain
2004
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
The skin: an indispensable barrier
2008 Standout
Deferiprone Does Not Protect against Chronic Anthracycline Cardiotoxicity in Vivo
2008
Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease
2012
METABOLISM OF THE ONE-RING OPEN METABOLITES OF THE CARDIOPROTECTIVE DRUG DEXRAZOXANE TO ITS ACTIVE METAL-CHELATING FORM IN THE RAT
2005
Anti-inflammatory Effects of Baicalin, Baicalein, and Wogonin In Vitro and In Vivo
2014
Activation of Platelet-Derived Growth Factor Receptor Alpha Contributes to Liver Fibrosis
2014
Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks
2006 Standout
Role of connexin-based gap junction channels and hemichannels in ischemia-induced cell death in nervous tissue
2004
Freeze-fracture and immunogold analysis of aquaporin-4 (AQP4) square arrays, with models of AQP4 lattice assembly
2004
Comprehensive analysis of kinase inhibitor selectivity
2011 Standout
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials
2015 Standout
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
2019 Standout
Gap junction channels coordinate the propagation of intercellular Ca2+ signals generated by P2Y receptor activation
2004
Prevention of Anthracycline-Induced Cardiotoxicity
2014
Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
2009 Standout
Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation
2013 Standout
The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients
2013
Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin
2006
ROS and the DNA damage response in cancer
2018 Standout
A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity
2014
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Receptor subtype discrimination using extensive shape complementary designed interfaces
2019 StandoutNobel
Consciousness in the universe
2013 StandoutNobel
Preservation of Fertility in Patients with Cancer
2009 Standout
Dexrazoxane prevents doxorubicin‐induced long‐term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats
2007
Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)
2013
A Novel COX‐2 Inhibitor Pyrazole Derivative Proven Effective as an Anti‐Inflammatory and Analgesic Drug
2010
The origin of extracellular fields and currents — EEG, ECoG, LFP and spikes
2012 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
2009
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia
2016
Connexins Are Critical for Normal Myelination in the CNS
2003
Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone
2008
Marine natural products
2015 Standout
Fast structural responses of gap junction membrane domains to AB5 toxins
2013 StandoutNobel
Iron is not involved in oxidative stress‐mediated cytotoxicity of doxorubicin and bleomycin
2006
Reactive species in non-equilibrium atmospheric-pressure plasmas: Generation, transport, and biological effects
2016 Standout
Plasma Membrane Channels Formed by Connexins: Their Regulation and Functions
2003
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Ferroptosis as a target for protection against cardiomyopathy
2019 Standout
Life cycle of connexins in health and disease
2006 Standout
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
2014
Connexin43 and connexin26 form gap junctions, but not heteromeric channels in co-expressing cells
2004
Advances in Copper Complexes as Anticancer Agents
2013 Standout
ELECTRICAL SYNAPSES IN THE MAMMALIAN BRAIN
2004
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
2012 Standout
Isolation of Lomaiviticins C–E, Transformation of Lomaiviticin C to Lomaiviticin A, Complete Structure Elucidation of Lomaiviticin A, and Structure–Activity Analyses
2012
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Cardiovascular toxicity of biologic agents for cancer therapy.
2014
Physiology of Microglia
2011 Standout
Topoisomerase IIβ–Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane
2007
Design of ordered two-dimensional arrays mediated by noncovalent protein-protein interfaces
2015 StandoutScienceNobel
Works of Daywin Patel being referenced
Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II)
2013
The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin
2004
The iron chelator Dp44mT does not protect myocytes against doxorubicin
2009
The Metabolites of the Cardioprotective Drug Dexrazoxane Do Not Protect Myocytes from Doxorubicin-Induced Cytotoxicity
2003
Dexrazoxane (ICRF-187) Protects Cardiac Myocytes Against Doxorubicin by Preventing Damage to Mitochondria
2003
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin
2003
The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent
2007
The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro
2010
The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II)
2014
Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib
2009
Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F
2007
Role of NADPH cytochrome P450 reductase in activation of RH1
2007
Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib
2008
Connexin26 in adult rodent central nervous system: Demonstration at astrocytic gap junctions and colocalization with connexin30 and connexin43
2001